Search 

IMS Health Capital (IMSHC) is a niche life-science focused investment bank which manages financing transactions, and advises on M&A and licensing/partnering transactions.

IMS Health Capital (IMSHC) is a fully owned subsidiary of IMS Health, Inc. (www.imshealth.com) and affiliated with IMS Consulting Group (www.imscg.com).

IMSHC has privileged access to a vast array of IMS Health’s resources and connections and can help prepare a compelling value proposition and put you in touch with the right interested parties.  Our team has extensive life-science industry experience and can provide support at any and all stages of the transaction process.  Unlike most investment banks or business development consultants, IMSHC has immense strategic partnering capabilities and can work with companies on both partnering and financing efforts.  Given our unique positioning and access to a vast array of information and relationships, we see a high volume of opportunities.

IMSHC is a SEC/FINRA licensed broker dealer and a wholly owned subsidiary of IMS Health, Inc.  IMS Health Inc. is publicly traded on the NYSE under the ticker “IMS”, and is the world’s leading information, services and technology company in the Life Sciences sector.  Customers of IMS Health’s data and consulting services include most of the top names in pharmaceutical, medical device and consumer health manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community (www.imshealth.com).

Our clients are early-stage biotechnology, medical device, diagnostics and pharmaceutical service companies. When we begin working with a client they are frequently looking to complete proof-of-concept studies, secure intellectual property and other critical preliminary tasks. Typically we raise the first round ($1 - $5 million of capital) needed to accomplish these milestones, usually, but not always from angel investors. After key milestones have been achieved using that money, we generally follow by raising a second round of $5-20 million, usually institutional money, for development and growth

By working this way, we increase our clients' success rate raising capital and building their companies and the returns to the investors we bring into those companies. We have raised over $80 million in early stage funding for our clients (in Seed, Series A and Series B rounds) and delivered realized returns, so far, over $500 million—a realized return to date of over 6X—to the investors who provided that early stage capital, with a number of the companies still driving towards an exit that may increase that figure. Realized (cash-on-cash) internal rates of return for a hypothetical investor who participated in each round of financing offered by WG&A to date exceeds 65% annually.